Trial Profile
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Multiple Doses of TAK-935 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jan 2022
Price :
$35
*
At a glance
- Drugs Soticlestat (Primary)
- Indications Epilepsy
- Focus Adverse reactions
- Sponsors Takeda
- 09 Jan 2022 Results assessing safety and tolerability of multiple escalating daily doses of soticlestat published in the British Journal of Clinical Pharmacology
- 27 Apr 2018 Results presented at the 70th Annual Meeting of the American Academy of Neurology
- 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society.